EP2934512A4 - Verwendung von cannabinoiden und terpenen zur behandlung von organophosphat- und carbamattoxizität - Google Patents

Verwendung von cannabinoiden und terpenen zur behandlung von organophosphat- und carbamattoxizität

Info

Publication number
EP2934512A4
EP2934512A4 EP13866227.5A EP13866227A EP2934512A4 EP 2934512 A4 EP2934512 A4 EP 2934512A4 EP 13866227 A EP13866227 A EP 13866227A EP 2934512 A4 EP2934512 A4 EP 2934512A4
Authority
EP
European Patent Office
Prior art keywords
organophosphate
cannabinoids
terpenes
treatment
carbamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13866227.5A
Other languages
English (en)
French (fr)
Other versions
EP2934512A1 (de
EP2934512B1 (de
Inventor
Joseph Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOTZKER CONSULTING LLC
Original Assignee
KOTZKER CONSULTING LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOTZKER CONSULTING LLC filed Critical KOTZKER CONSULTING LLC
Publication of EP2934512A1 publication Critical patent/EP2934512A1/de
Publication of EP2934512A4 publication Critical patent/EP2934512A4/de
Application granted granted Critical
Publication of EP2934512B1 publication Critical patent/EP2934512B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP13866227.5A 2012-12-18 2013-12-18 Verwendung von cannabinoiden und terpenen zur behandlung von organophosphat- und carbamattoxizität Active EP2934512B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261738782P 2012-12-18 2012-12-18
PCT/US2013/076223 WO2014100231A1 (en) 2012-12-18 2013-12-18 Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity

Publications (3)

Publication Number Publication Date
EP2934512A1 EP2934512A1 (de) 2015-10-28
EP2934512A4 true EP2934512A4 (de) 2016-10-19
EP2934512B1 EP2934512B1 (de) 2021-11-24

Family

ID=50979163

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13866227.5A Active EP2934512B1 (de) 2012-12-18 2013-12-18 Verwendung von cannabinoiden und terpenen zur behandlung von organophosphat- und carbamattoxizität

Country Status (5)

Country Link
US (4) US20150313868A1 (de)
EP (1) EP2934512B1 (de)
CA (1) CA2895805A1 (de)
IL (1) IL238946B (de)
WO (1) WO2014100231A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US8096432B2 (en) 2007-05-01 2012-01-17 Wabtec Holding Corp Elastomeric draft gear having a housing
CA2895805A1 (en) * 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
US10639439B2 (en) * 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
WO2015074137A1 (en) * 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
WO2016187722A1 (en) * 2015-05-27 2016-12-01 Mary Lynch Use of cannabinoids in the treatment of ocular inflammation and/or pain
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
KR102267997B1 (ko) 2013-12-23 2021-06-23 쥴 랩스, 인크. 기화 디바이스 시스템 및 방법
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US20160366947A1 (en) 2013-12-23 2016-12-22 James Monsees Vaporizer apparatus
AU2015279612A1 (en) 2014-06-27 2017-02-02 Kenton L. Crowley Buccal and sublingual cannabinoid formulations and method of making the same
WO2016036724A1 (en) * 2014-09-02 2016-03-10 The Texas A&M University System Method of treating organophosphate intoxication
BR122021018502B1 (pt) 2014-10-21 2022-05-03 United Cannabis Corp Formulação de canabinoide líquida
KR102627987B1 (ko) 2014-12-05 2024-01-22 쥴 랩스, 인크. 교정된 투여량 제어
US10350165B2 (en) * 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
MX395015B (es) * 2014-12-12 2025-03-24 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides
CN105802951B (zh) * 2014-12-30 2021-03-05 丰益(上海)生物技术研发中心有限公司 固定化脂肪酶及其制备方法和用途
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
AU2016225026A1 (en) 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
CA2991530C (en) * 2015-07-06 2023-12-12 Cg-Bio Genomics, Inc. Supplement compositions comprising oils, cannabis and herbal extracts, and uses thereof
CA3012679C (en) * 2016-01-29 2023-12-12 Mannkind Corporation Dry powder inhaler
MX377347B (es) 2016-02-11 2025-03-07 Juul Labs Inc Cartucho rellenable de vaporizador y metodo de relleno
AU2017216928B2 (en) * 2016-02-11 2018-09-20 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof
WO2017139675A1 (en) 2016-02-11 2017-08-17 Pax Labs, Inc. Securely attaching cartridges for vaporizer devices
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
PT3429580T (pt) * 2016-03-16 2025-08-12 Buzzelet Development And Technologies Ltd Composição de canabinoides enriquecida em terpenos
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
NZ749229A (en) * 2016-06-15 2026-01-30 Ojai Energetics Pbc Methods and compositions for reducing oxidative stress
EP4556457A3 (de) * 2016-06-15 2025-06-18 Ojai Energetics PBC Verfahren und zusammensetzungen zur potenzierung von stammzellentherapien
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD848057S1 (en) 2016-06-23 2019-05-07 Pax Labs, Inc. Lid for a vaporizer
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
JP2019523282A (ja) * 2016-08-03 2019-08-22 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
SG11201900665VA (en) 2016-08-03 2019-02-27 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US12485129B2 (en) 2016-08-29 2025-12-02 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
MX380850B (es) 2016-08-29 2025-03-12 Canopy Growth Corp Composiciones solubles en agua que comprenden cannabinoides purificadas
WO2018057596A1 (en) * 2016-09-21 2018-03-29 JC Pharma, Inc. Method and composition for acute treatment of seizures
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
US10350200B2 (en) * 2017-01-23 2019-07-16 Southwest Research Institute Aqueous suspensions of oximes for autoinjectors
BR112019026877A2 (pt) 2017-06-19 2020-06-30 Zelda Therapeutics Operations Pty Ltd composições para distúrbios do sono e tratamentos do mesmo
EP3443956A1 (de) * 2017-08-18 2019-02-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verbindung zum erhöhen der endocannabinoidkonzentration bei einer person zur verwendung zur vorbeugung und/oder behandlung einer sozialen verhaltensstörung
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
WO2019089583A1 (en) * 2017-10-30 2019-05-09 Endocanna Health, Inc. Cannabinoid formulations
WO2019118205A1 (en) * 2017-12-12 2019-06-20 Daisy Pharma Opioid Venture, Llc Opioid enhancing and/or sparing method from co-administered or fixed-dose combinations of dronabinol and an opioid
WO2019159174A1 (en) * 2018-02-16 2019-08-22 Icdpharma Ltd. Colonic delivery of cannabinoids in solid solution compositions
WO2019220324A2 (en) * 2018-05-14 2019-11-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid compositions and uses thereof in the treatment of infectious conditions
AU2018100924A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
AU2018100925A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Cannabinoid composition and method for treating PTSD and/or anxiety
US20200069618A1 (en) * 2018-09-04 2020-03-05 John C. Gustin Compositions having an agent and an enhancer thereof, methods of use, and delivery systems
US20210393572A1 (en) * 2018-09-28 2021-12-23 Visceral Therapeutics Inc. Pharmaceutically active cannabis-based compositions and methods of use for treating gastrointestinal conditions
EP3876907A4 (de) * 2018-11-07 2022-08-10 Columbia Care LLC Zäpfchenformulierungen mit cannabinoid
CN117695226A (zh) 2018-12-11 2024-03-15 迪斯拉普申实验室公司 用于递送治疗剂的组合物及其使用方法和制备方法
GB2615034A (en) 2018-12-18 2023-07-26 Ojai Energetics Pbc Cannabinoid compositions for virtual and augmented reality experiences
US11147805B2 (en) * 2019-02-07 2021-10-19 Medipure Pharmaceuticals Inc. Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product
US11433063B1 (en) * 2019-03-12 2022-09-06 Belhaven Biopharma, Inc. Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides
EP3986396A4 (de) * 2019-06-18 2023-08-02 Opiant Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von akuter cannabinoid-überdosis mit einem cannabinoid-rezeptorantagonisten
WO2020257336A1 (en) 2019-06-18 2020-12-24 Opiant Pharmaceuticals, Inc. Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist
WO2021127749A1 (en) * 2019-12-24 2021-07-01 Cannadol Pharmaceuticals Ltd Compositions comprising terpenes and their use in the treatment or alleviation of pain or anxiety
US12268659B2 (en) 2020-03-04 2025-04-08 Pleopharma, Inc. Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal
CN115605195A (zh) 2020-03-04 2023-01-13 普利欧制药有限公司（Us） 用于治疗大麻使用病症和缓解大麻素戒断的方法和组合物
CN115968278A (zh) 2020-05-18 2023-04-14 麦氏生物科技有限公司 脂质-聚合物组合物及使用方法
WO2021243309A1 (en) * 2020-05-28 2021-12-02 Sollievo Pharmaceuticals, Inc Parenteral delivery of avizafone
CA3194409A1 (en) * 2020-10-05 2022-04-14 Sunil Shah Cannabinoid-containing compositions and use for treating and preventing diseases
WO2022103639A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
EP4406934A4 (de) * 2021-09-15 2025-08-13 Kangwon Univ Industry Cooperation Foundation Neuartiges cannabidiolderivat, verfahren zur herstellung davon und zusammensetzung zur verbesserung der kognitiven funktion damit
CA3239288A1 (en) * 2021-11-05 2023-05-11 Nicholas T. Monsul Materials and methods for preventing or reducing toxicity to organophosphates and other toxic materials
IL315021A (en) * 2022-02-16 2024-10-01 Beyond Barriers Therapeutics Inc Administration of an antioxidant compound for the treatment of seizures, viral infections, exposure to chemical warfare agents, and other conditions
EP4665718A1 (de) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Kleine moleküle als inhibitoren der monoacylglycerol-lipase (magl), zusammensetzungen und verwendung davon

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120295968A1 (en) * 2011-05-20 2012-11-22 Brooks Kelly Research, Llc Pharmaceutical Composition Comprising Cannabinoids

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096740A (en) 1990-11-06 2000-08-01 Ramot University Authority For Applied Research And Industrial Development Ltd. Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US6211230B1 (en) 1999-09-27 2001-04-03 The United States Of America As Represented By The Secretary Of The Army Method of reducing brain damage resulting from seizures
US6369052B1 (en) 2000-08-07 2002-04-09 Georgetown University Combination of huperzine and nicotinic compounds as a neuroprotective agent
AU2002331595A1 (en) 2001-08-15 2003-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Novel vasoconstrictor cannabinoid analogs
EP1482917B1 (de) 2002-02-01 2019-05-08 GW Pharma Limited Zusammensetzungen mit cannabidiolsäure zur behandlung von übelkeit, erbrechen, emesis, reisekrankheit oder ähnlichen zuständen
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
AU2004305518A1 (en) * 2003-12-15 2005-07-07 Alexza Pharmaceuticals, Inc. Treatment of breakthrough pain by drug aerosol inhalation
CA2578709C (en) * 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
AU2006308889A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2439393B (en) 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
US9035130B2 (en) 2007-05-31 2015-05-19 Gw Pharma Limited Reference plant, a method for its production, extracts obtained therefrom and their use
GB2450741A (en) 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
WO2009059018A1 (en) 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
US20110257256A1 (en) 2008-07-31 2011-10-20 Bionoria Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
US20120231083A1 (en) * 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
CA2895805A1 (en) * 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
GB2513167B (en) 2013-04-18 2016-03-02 Otsuka Pharma Co Ltd Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
US9956182B2 (en) 2013-05-02 2018-05-01 Mor Research Applications Ltd. Cannabidiol for the prevention and treatment of graft-versus-host disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120295968A1 (en) * 2011-05-20 2012-11-22 Brooks Kelly Research, Llc Pharmaceutical Composition Comprising Cannabinoids

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CHANG ET AL: "Quantitative structure-activity relationship (QSAR) for neuroprotective activity of terpenoids", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 80, no. 9, 27 January 2007 (2007-01-27), pages 835 - 841, XP005864168, ISSN: 0024-3205, DOI: 10.1016/J.LFS.2006.11.009 *
EYER FLORIAN ET AL: "Obidoxime in acute organophosphate poisoning: 1-clinical effectiveness", CLINICAL TOXICOLOGY, INFORMA HEALTHCARE, US, vol. 47, no. 8, 1 September 2009 (2009-09-01), pages 798 - 806, XP009191557, ISSN: 1556-3650 *
FISCHEDICK JUSTIN ET AL: "Cannabinoid Receptor 1 Binding Activity and Quantitative Analysis of Cannabis sativa L. Smoke and Vapor", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 58, no. 2, 1 February 2010 (2010-02-01), pages 201 - 207, XP009146900, ISSN: 0009-2363, [retrieved on 20091124] *
HORST THEIRMANN ET AL: "Comments on " Efficacy of two new asymmetric bispyridinium oximes (K-27 and K-48) in rats exposed to diisopropylfluorophosphate: Comparison with pralidoxime, obidoxime, trimedoxime, methoxime, and HI 6 "", TOXICOLOGY MECHANISMS AND METHODS, vol. 19, no. 4, 1 May 2009 (2009-05-01), US, pages 334 - 334, XP055300145, ISSN: 1537-6516, DOI: 10.1080/15376510902941881 *
JUN D ET AL: "Commercially available antidotes of organophosphate poisonings (pralidoxime, obidoxime, methoxime, trimedoxime and HI-6) and newly developed oxime K027 as reactivators of human acetylcholinesterase inhibited by selected organophosphate pesticides", TOXICOLOGY LETTERS, ELSEVIER BIOMEDICAL PRESS, AMSTERDAM, NL, vol. 189, 13 September 2009 (2009-09-13), pages S217, XP026420598, ISSN: 0378-4274, [retrieved on 20090731] *
KURTZ ET AL: "Pralidoxime in the treatment of carbamate intoxication", AMERICAN JOURNAL OF EMERGENCY MEDICINE, CENTRUM PHILADELPHIA, PA, US, vol. 8, no. 1, 1 January 1990 (1990-01-01), pages 68 - 70, XP026125154, ISSN: 0735-6757, [retrieved on 19900101], DOI: 10.1016/0735-6757(90)90299-F *
LINNZI K.M. WRIGHT ET AL: "Behavioral sequelae following acute diisopropylfluorophosphate intoxication in rats: Comparative effects of atropine and cannabinomimetics", NEUROTOXICOLOGY AND TERATOLOGY, vol. 32, no. 3, 1 May 2010 (2010-05-01), US, pages 329 - 335, XP055269072, ISSN: 0892-0362, DOI: 10.1016/j.ntt.2009.12.006 *
NALLAPANENI A ET AL: "Modulation of paraoxon toxicity by the cannabinoid receptor agonist WIN 55,212-2", TOXICOLOGY, LIMERICK, IR, vol. 227, no. 1-2, 3 October 2006 (2006-10-03), pages 173 - 183, XP027919186, ISSN: 0300-483X, [retrieved on 20061003] *
NALLAPANENI A ET AL: "Pharmacological enhancement of endocannabinoid signaling reduces the cholinergic toxicity of diisopropylfluorophosphate", NEUROTOXICOLOGY, TOX PRESS, RADFIELD, AR, IN, vol. 29, no. 6, 1 November 2008 (2008-11-01), pages 1037 - 1043, XP025680406, ISSN: 0161-813X, [retrieved on 20080813], DOI: 10.1016/J.NEURO.2008.08.001 *
NEWMARK J: "Nerve agents", NEUROLOGIC CLINICS, ELSEVIER SCIENCE, US, vol. 23, no. 2, 1 May 2005 (2005-05-01), pages 623 - 641, XP009191555, ISSN: 0733-8619 *
SADRI SOHEIL ET AL: "Cannabinoid Receptor Agonist WIN-55,212-2 Protects Differentiated PC12 Cells From Organophosphorus-Induced Apoptosis", INTERNATIONAL JOURNAL OF TOXICOLOGY,, vol. 29, no. 2, 1 March 2010 (2010-03-01), pages 201 - 208, XP009189837, ISSN: 1091-5818 *
See also references of WO2014100231A1 *
THABET H ET AL: "Comparative study of two dosage regimens of pralidoxime in human organophosphate poisonings", TOXICOLOGY LETTERS, ELSEVIER BIOMEDICAL PRESS, AMSTERDAM, NL, vol. 164, 20 September 2006 (2006-09-20), pages S122, XP024937889, ISSN: 0378-4274, [retrieved on 20060920], DOI: 10.1016/J.TOXLET.2006.06.257 *

Also Published As

Publication number Publication date
US11464758B2 (en) 2022-10-11
US20150313868A1 (en) 2015-11-05
EP2934512A1 (de) 2015-10-28
IL238946B (en) 2019-03-31
WO2014100231A1 (en) 2014-06-26
IL238946A0 (en) 2015-07-30
US11266623B2 (en) 2022-03-08
CA2895805A1 (en) 2014-06-26
US20220151981A1 (en) 2022-05-19
US20180311205A1 (en) 2018-11-01
EP2934512B1 (de) 2021-11-24
US20200375940A1 (en) 2020-12-03
US12150928B2 (en) 2024-11-26

Similar Documents

Publication Publication Date Title
EP2934512A4 (de) Verwendung von cannabinoiden und terpenen zur behandlung von organophosphat- und carbamattoxizität
FR25C1016I2 (fr) Utilisation de l&#39;inhibiteur de la télomérase imetelstat pour le traitement du syndrome myélodysplasique
EP2818482A4 (de) Pharmazeutische zusammensetzung zur behandlung und/oder prävention von krebs
EP2818481A4 (de) Pharmazeutische zusammensetzung zur behandlung und/oder prävention von krebs
EP2824114A4 (de) Pharmazeutische zusammensetzung zur behandlung und/oder prävention von krebs
EP2836226A4 (de) Zusammensetzungen und verfahren zur behandlung von hämoglobinopathien
EP2818483A4 (de) Medizinische zusammensetzung zur behandlung oder prävention von krebs
EP2931268A4 (de) Gamma-hydroxybutyrat-zusammensetzungen und verwendung zur behandlung von störungen
EP2832366A4 (de) Pharmazeutische zusammensetzung zur behandlung und/oder prävention von gallenblasenkrebs
EP2830646A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen
EP3288592A4 (de) Verwendung von cannabidiol zur behandlung von kindlichen spasmen
EP2875826A4 (de) Zusammensetzung zur vorbeugung oder behandlung von sepsis
EP2828247A4 (de) Verbindungen zur behandlung von spinaler muskelatrophie
EP2819519A4 (de) Verbindungen zur behandlung von spinaler muskelatrophie
EP2832365A4 (de) Pharmazeutische zusammensetzung zur behandlung und/oder prävention von leberkrebs
EP2836482A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP2922591A4 (de) Behandlung von thalamokortikaler dysrhythmie
EP2911753A4 (de) Therapievorrichtung zur kieferklemmenvorbeugung und -behandlung
EP2919788A4 (de) Verfahren und zusammensetzungen zur behandlung von schizophrenie
EP2870161A4 (de) Oxabicycloheptane und oxabicycloheptene zur behandlung von reperfusionsschäden
EP2852571A4 (de) Zusammensetzungen und verfahren zur behandlung von mukositis
FR3013184B1 (fr) Utilisation d&#39;hydroxyapatite pour le traitement de l&#39;esca
EP2837381A4 (de) Verwendung von mitteln zur behandlung von krebs, die die peritumoralumgebung verändern
EP2976072A4 (de) Feine epinephrinteilchen und verfahren zur verwendung davon zur behandlung von auf epinephrin reagierenden zuständen
EP2702992A4 (de) Verwendung von melatonin zur behandlung und/oder vorbeugung von mucositis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/00 20060101ALI20160510BHEP

Ipc: A61K 31/352 20060101AFI20160510BHEP

Ipc: C07D 451/10 20060101ALI20160510BHEP

Ipc: C07D 471/08 20060101ALI20160510BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20160920

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/00 20060101ALI20160914BHEP

Ipc: C07D 451/10 20060101ALI20160914BHEP

Ipc: A61K 31/352 20060101AFI20160914BHEP

Ipc: C07D 471/08 20060101ALI20160914BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180717

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210709

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1449320

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013080217

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20211124

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1449320

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220224

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220324

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220324

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220224

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220225

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013080217

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211218

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211218

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

26N No opposition filed

Effective date: 20220825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20131218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211124

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251229

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20251230

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20251226

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20251231

Year of fee payment: 13